Monday, September 3, 2012

World Vaccines Market 2012-2022

World Vaccines Market 2012-2022

NEW YORK, Sept. 3, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

World Vaccines Market 2012-2022

http://www.reportlinker.com/p0578539/World-Vaccines-Market-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Report Details

Why the vaccine market can expand - you discover its commercial potential

Where is the vaccines sector heading? Visiongain's report shows you forecasted revenues to 2022. You see data, trends, opportunities and industry prospects.

Our new study investigates vaccines for human beings, letting you assess projected sales at overall world market, submarket, product and national level. Many segments hold growth potential.

Analysis of submarkets and products

In addition to the overall market, you see revenue forecasting of four world-level submarkets to 2022: 

• Paediatric vaccines

• Influenza vaccines

• Adult prophylactic vaccines

• Therapeutic vaccines.

Also, how will 12 leading products and branded groups - including Prevnar-13, Pentacel, Gardasil and Fluzone - perform to 2022? Our investigation shows business research and analysis with sales forecasts and discussions. 

What are the prospects in leading regions and countries? 

There are many commercial opportunities in developed and developing countries. You discover revenue forecasts to 2022 for eleven national markets:

• US

• Japan

• Germany, France, UK, Spain and Italy (EU5)

• Brazil, Russia, India and China (BRIC).

New products from 2012 onwards will benefit world, regional and national markets.

Coverage of research and development

What about the R&D pipeline? You see developmental trends there:

• Paediatric applications

• Influenza

• HPV

• Adult prophylactic agents

• HIV

• Pneumococcal products

• Therapeutic vaccines.

Technology and other progress will change the sector. The report explains. 

What issues affect the vaccines industry and market?

Our study lets you assess industry trends and outlooks worldwide from 2012. You see many discussions:

• Manufacturing, storage, distribution and supply

• Emerging applications, including cancers

• Payers and pricing

• Safety and regulators

• Technologies - antigens, adjuvants and delivery systems

• Policy, pandemics and other issues.

Leading companies and revenue prospects 

From 2012 to 2022, biopharma companies will increase the industry's revenues. More vaccination of adults and use of therapeutic vaccines in cancer treatment will stimulate the market.

The R&D pipeline is strong. Also, leading brands retain potential. Our report predicts strong growth in the market's revenues from 2012 to 2022. 

Our work discusses Sanofi Pasteur, Pfizer, GSK, Merck and other vaccine developers and manufacturers. This decade, many opportunities will arise for companies.

Commercial news, developmental trends and sales forecasting

In the report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP), R&D and commercial developments. You receive 91 tables, 63 charts and a research interview.

Eight ways World Vaccines Market 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:

• Find potential revenues to 2022 for the overall world market and submarkets

• Discover projected revenues of leading products to 2022

• See market forecasting to 2022 for US, Japan, Germany, France, UK, Spain and Italy (EU5), Brazil, Russia, India and China (BRIC)

• Assess companies, discovering activities and outlooks

• Review R&D pipelines, seeing trends

• View opinions on the sector, including a research interview

• Investigate competition and opportunities influencing sales

• Find out what stimulates and restrains the industry and market.

There you find quantitative and qualitative analyses with independent predictions. You receive information unique to our report, helping you stay informed on business intelligence.

Gain research and analysis for vaccines now

Visiongain's study is for everybody needing industry and market analyses for vaccines. You find data, trends and predictions there. Please order that report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6 

Table of Contents

1. Executive Summary

1.1 Overview of Findings

1.2 Report Contents

1.3 Research and Analysis Methods

2. Introduction to the Vaccines Market in 2012

2.1 A Brief History of Vaccines

2.2 How Vaccines Work: The Immune System and Natural Immunity

2.2.1 Vaccines Create Artificial Immunity 

2.3 Types of Vaccine

2.3.1 Live, Attenuated Vaccines

2.3.2 Recombinant Live Vaccines

2.3.3 Inactivated Vaccines

2.3.4 Toxoid Vaccines

2.3.5 Subunit Vaccines

2.3.6 Conjugate Vaccines

2.3.7 Recombinant Subunit Vaccines

2.3.8 DNA Vaccines

2.3.9 Recombinant Vector Vaccines

2.3.10 Therapeutic Vaccines

3. World Vaccines Market: Overview 2012-2022

3.1 World Vaccines Market Forecast, 2012-2022

3.2 Market Segmentation, 2012-2022

3.3 Leading Companies in the Market, 2012

3.3.1 GlaxoSmithKline, 2012

3.3.2 Sanofi Pasteur, 2012

3.3.3 Pfizer, 2012

3.3.4 Merck, 2012

3.3.5 Novartis, 2012

3.3.6 Other Vaccine Manufacturers, 2012

3.4 The US, Japan and Other Leading National Markets, 2011-2022

3.4.1 EU5 National Market Breakdown, 2011-2022

3.4.2 BRIC National Market Breakdown, 2011-2022

4. Paediatric Vaccines Market, 2012-2022

4.1 Paediatric Vaccines Market Forecast, 2012-2022

4.2 Paediatric Vaccines Market Overview, 2012

4.2.1 Leading Companies in the Paediatric Vaccines Segment, 2012

4.2.2 Regional Variations in the Paediatric Vaccines Segment, 2012

4.2.3 Drivers and Restraints in the Paediatric Vaccines Segment, 2012

4.3 Leading Products in the Paediatric Vaccines Segment, 2012-2022

4.3.1 Prevnar-13 (Pfizer)

4.3.1.1 Drivers and Restraints for Prevnar-13, 2012

4.3.1.2 Market Forecast for Prevnar-13, 2012-2022

4.3.2 Pentacel/Pediacel/Pentaxim/Others (Sanofi Pasteur)

4.3.2.1 Drivers and Restraints for Pentacel/Pediacel/Pentaxim/Others, 2012

4.3.2.2 Market Forecast for Pentacel/Pediacel/Pentaxim/Others, 2012-2022

4.3.3 Proquad/MMR-II/Varivax (Merck)

4.3.3.1 Drivers and Restraints for ProQuad/MMR-II/Varivax 2012

4.3.3.2 Market Forecast for ProQuad/MMR-II/Varivax, 2012-2022

4.3.4 Infanrix/Pediarix/Others (GlaxoSmithKline)

4.3.4.1 Drivers and Restraints for Infanrix/Pediarix/Others, 2012

4.3.4.2 Market Forecast for Infanrix/Pediarix/Others 2012-2022

4.3.5 RotaTeq (Merck)

4.3.5.1 Drivers and Restraints for RotaTeq, 2012

4.3.5.2 Market Forecast for RotaTeq 2012-2022

4.3.6 Other Paediatric Vaccines

4.4 Paediatric Vaccines Pipeline, 2012

4.4.1 Bexsero (Novartis) 

4.4.2 Hexaxim (Sanofi Pasteur)

4.4.3 Menveo Infants (Novartis) 

4.4.4 MenHibrix (GlaxoSmithKline) 

4.4.5 Mosquirix (GlaxoSmithKline) 

4.4.6 V419 (Merck)

4.4.7 Ixiaro (Intercell)

4.4.8 Nimenrix (GlaxoSmithKline)

4.4.9 Quadracel (Sanofi Pasteur)

4.4.10 V212 (Merck)

4.4.11 Other Paediatric Vaccine Pipeline Products, 2012

4.5 Segment Revenues by Product, 2012-2022: Summary

5. Influenza Vaccines Market, 2012-2022

5.1 Influenza Vaccines Market Forecast, 2012-2022

5.2 Influenza Vaccines Market Overview, 2012

5.2.1 Leading Companies in the Influenza Vaccines Segment, 2012

5.2.2 Regional Variations in the Influenza Vaccines Segment, 2012

5.2.3 Drivers and Restraints in the Influenza Vaccines Segment, 2012

5.3 Leading Products in the Influenza Vaccines Market, 2012

5.3.1 Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others (Sanofi Pasteur)

5.3.1.1 Drivers and Restraints for Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others (Sanofi Pasteur), 2012

5.3.1.2 Market Forecast for Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others, 2012-2022

5.3.2 Fluarix/Flulaval (GlaxoSmithKline)

5.3.2.1 Drivers and Restraints for Fluarix/Flulaval, 2012

5.3.2.2 Market Forecast for Fluarix/Flulaval, 2012

5.3.3 Other Seasonal Influenza Vaccines, 2012

5.3.4 Pandemic Influenza Vaccines, 2012

5.4 Influenza Vaccines Pipeline, 2012

5.5 Segment Revenues by Product, 2012-2022: Summary

6. Adult Prophylactic Vaccines Market, 2012-2022

6.1 Adult Prophylactic Vaccines Market Forecast, 2012-2022

6.2 Adult Prophylactic Vaccines Market Overview, 2012

6.2.1 Leading Companies in the Adult Prophylactic Vaccines Segment, 2012

6.2.2 Regional Variations in the Adult Prophylactic Vaccines Segment, 2012

6.2.3 Drivers and Restraints in the Adult Prophylactic Vaccines Segment, 2012

6.3 Leading Products in the Adult Prophylactic Vaccines Segment, 2012

6.3.1 Gardasil (Merck)

6.3.1.1 Drivers and Restraints for Gardasil, 2012

6.3.1.2 Market Forecast for Gardasil, 2012-2022

6.3.2 Engerix/Fendrix/Havrix/Twinrix/Ambirix (GlaxoSmithKline)

6.3.2.1 Drivers and Restraints for Engerix/Fendrix/Havrix/Twinrix/Ambirix, 2012

6.3.2.2 Market Forecast for Engerix/Fendrix/Havrix/Twinrix/Ambirix, 2012-2022

6.3.3 Cervarix (GlaxoSmithKline)

6.3.3.1 Drivers and Restraints for Cervarix, 2012

6.3.3.2 Market Forecast for Cervarix, 2012-2022

6.3.4 Menactra and Other Meningitis/Pneumonia Vaccines (Sanofi Pasteur)

6.3.4.1 Drivers and Restraints for Menactra and Other Meningitis/Pneumonia Vaccines, 2012

6.3.4.2 Market Forecast for Menactra and Other Meningitis/Pneumonia Vaccines, 2012-2022

6.3.5 Adacel and Other Adult Boosters (Sanofi Pasteur)

6.3.5.1 Drivers and Restraints for Adacel and Other Adult Boosters, 2012

6.3.5.2 Market Forecast for Adacel and Other Adult Boosters, 2012-2022

6.3.6 Other Adult Prophylactic Vaccines

6.4 Adult Prophylactic Vaccines Pipeline, 2012 

6.4.1 GSK1437173A (GlaxoSmithKline)

6.4.2 BioThrax (Emergent BioSolutions)

6.4.3 Dengue Fever Vaccine (Sanofi Pasteur)

6.4.4 Heplisav (Dynavax Technologies)

6.4.5 V503 (Merck)

6.4.6 Other Pipeline Adult Prophylactic Vaccines, 2012

6.5 Segment Revenues by Product, 2012-2022: Summary

7. Therapeutic Vaccines Market, 2012-2022

7.1 Therapeutic Vaccines Market Forecast, 2012-2022

7.2 Therapeutic Vaccines Market Overview, 2012

7.2.1 Leading Companies in the Therapeutic Vaccines Segment, 2012

7.2.2 Regional Variations in the Therapeutic Vaccines Segment, 2012

7.2.3 Drivers and Restraints in the Therapeutic Vaccines Segment, 2012

7.3 Provenge: Leading Therapeutic Vaccine, 2011

7.3.1 Drivers and Restraints for Provenge, 2012

7.3.2 Market Forecast for Provenge, 2012-2022

7.4 Therapeutic Vaccines Pipeline, 2012

7.4.1 Abagovamab (Menarini)

7.4.2 MAGE-A3 (GlaxoSmithKline)

7.4.3 BioVaxID (Biovest International)

7.4.4 DCVax-Prostate (NorthWest Biotherapeutics)

7.4.5 GVAX Prostate (Biosante Pharmaceuticals)

7.4.6 HyperAcute Pancreas (New Look Genetics)

7.4.7 IMA901 (Immatics Biotechnology)

7.4.8 Lucanix (Novarx)

7.4.9 M200 Prophage Cancer Vaccine (Agenus)

7.4.10 MVax (Avax Technologies)

7.4.11 Neuvax (Galena Biopharma)

7.4.12 Polyclonal Antibody Stimulator (Cancer Advances)

7.4.13 PROSTVAC (Bavarian Nordic)

7.4.14 Rindopepimut (Celldex Therapeutics)

7.4.15 Stimuvax (EMD Serono)

7.4.16 CVac (Prima Biomed)

7.4.17 Other Therapeutic Cancer Vaccines

7.4.18 Therapeutic Allergy Vaccines

7.4.19 Grass Pollen Extract Sublingual Vaccine (Stallergenes)

7.4.20 Pollinex Quattro (Allergy Therapeutics)

7.4.21 Ragweed Allergy Vaccine (Greer Laboratories)

7.4.22 Ragweed Allergy Vaccine and Grass Pollen Allergy Vaccine (ALK Abello)

7.4.23 Therapeutic Addiction Vaccines

7.4.24 NicVAX (Nabi Biopharmaceuticals)

7.4.25 Therapeutic Chronic Infectious Disease Vaccines

7.4.26 Therapeutic Vaccines for Other Chronic Disease 

7.5 Segment Revenues by Product, 2012-2022: Summary

8. Industry Trends, 2012-2022

8.1 Strengths: Vaccines are a Major Ongoing Healthcare Success Story

8.2 Weaknesses: High Costs and Uncertainties in Vaccine Manufacture, Storage and Supply

8.3 Opportunities: Vaccines are Annexing New Therapeutic Areas, and Have Advantages for Market Growth

8.4 Threats: Premium-Priced Vaccines Must Convince Regulators and Payers

8.5 Social: Vaccines Excite Unwarranted Controversy

8.6 Technological: New Antigens, New Adjuvants, New Delivery Systems

8.7 Economic: Rise of the Vaccine-Developing Countries 

8.8 Political: Vaccines in National and International Policy

9. Research Interview

9.1 Interview with Dr Louis Picker, Associate Director of OHSU's Vaccine and Gene Therapy Institute

9.1.1 The Basic Challenge of Developing an HIV Vaccine

9.1.2 Early Interception of HIV Infections via Antibodies

9.1.3 Early Interception of HIV Infections via T-Cells

9.1.4 The Use of CMV as a Vaccine Vector

9.1.5 The Effectiveness of the Vaccine in Humans

9.1.6 The Pre-Exposure Prophylactic Use of Anti-Retroviral Drugs as an Alternative Strategy

9.1.7 The Timeline for a Human Trial of the Vaccine

10. Conclusions

10.1 The Vaccine Market Will Show Strong Growth Through to 2022

10.2 Therapeutic Vaccines Will Increase Market Share

10.3 Prevnar-13

10.4 The Vaccine Pipeline is Strong

10.5 Concluding Remarks

List of Tables

Table 2.1 Timeline of Key Events in Vaccine Development, c.1000 AD - Present

Table 3.1 World Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016

Table 3.2 World Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022

Table 3.3 World Vaccines Market Segments: Revenues ($bn), Overall Market Shares (%), 2011

Table 3.4 World Vaccines Market Segments: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016

Table 3.5 World Vaccines Market Segments: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022

Table 3.6 Leading Companies in the Vaccines Market: Revenues ($bn), Overall Market Shares (%), 2011

Table 3.7 Leading Regions in the Vaccines Market: Revenues ($bn), Overall Market Shares (%), 2011

Table 3.8 World Vaccines Market Regions: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016

Table 3.9 World Vaccines Market Regions: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022

Table 3.10 EU5 Vaccines Market Breakdown by Country: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016

Table 3.11 EU5 Vaccines Market Breakdown by Country: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2022

Table 3.12 BRIC Vaccines Market Breakdown by Country: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016

Table 3.13 BRIC Vaccines Market Breakdown by Country: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2022

Table 4.1 Paediatric Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016

Table 4.2 Paediatric Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022

Table 4.3 Leading Products in the Paediatric Vaccines Market: Revenues ($bn), Market Shares (%), 2011

Table 4.4 Leading Products in the Pneumococcal Vaccines Market: Revenues ($bn), Market Shares (%), 2011

Table 4.5 Pipeline Pneumococcal Vaccines, 2012

Table 4.6 Prevnar-13: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 4.7 Prevnar-13: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 4.8 Pipeline Paediatric Combination Vaccines, 2012

Table 4.9 Pentacel/Pediacel/Pentaxim/Others: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 4.10 Pentacel/Pediacel/Pentaxim/Others: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 4.11 ProQuad /MMR-II/Varivax Revenues ($bn), 2009-2011

Table 4.12 ProQuad/MMR-II/Varivax: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 4.13 ProQuad/MMR-II/Varivax: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 4.14 Infanrix/Pediarix/Others Revenues ($bn), AGR (%), Share of Total (%), by Region, 2011

Table 4.15 Infanrix/Pediarix/Others: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 4.16 Infanrix/Pediarix/Others: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 4.17 RotaTeq: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 4.18 RotaTeq: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 4.19 Other Paediatric Vaccines: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 4.20 Other Paediatric Vaccines: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 4.21 Selected Late-Stage Paediatric Vaccines Pipeline, 2012

Table 4.22 Selected Phase I and Phase II Paediatric Vaccines Pipeline, 2012

Table 4.23 Summary of Leading Products in the Paediatric Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 4.24 Summary of Leading Products in the Paediatric Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 5.1 Influenza Vaccines: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016

Table 5.2 Influenza Vaccines: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022

Table 5.3 Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 5.4 Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 5.5 Fluarix/Flulaval: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 5.6 Fluarix/Flulaval: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 5.7 Selected Products in the Influenza Vaccines Pipeline, 2012

Table 5.8 Summary of Leading Products in the Influenza Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 5.9 Summary of Leading Products in the Influenza Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 6.1 Adult Prophylactic Vaccines: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016

Table 6.2 Adult Prophylactic Vaccines: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022

Table 6.3 Leading Products in the Adult Prophylactic Vaccines Market: Revenues ($bn), Market Shares (%), 2011

Table 6.4 Pipeline HPV Vaccines, 2012

Table 6.5 Gardasil: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 6.6 Gardasil: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 6.7 Engerix/Fendrix/Havrix/Twinrix/Ambirix: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 6.8 Engerix/Fendrix/Havrix/Twinrix/Ambirix: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 6.9 Cervarix: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 6.10 Cervarix: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 6.11 Menactra and Other Meningitis/Pneumonia Vaccines: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 6.12 Menactra and Other Meningitis/Pneumonia Vaccines: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 6.13 Adacel and Other Adult Boosters: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 6.14 Adacel and Other Adult Boosters: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 6.15 Other Adult Prophylactic Vaccines: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 6.16 Other Adult Prophylactic Vaccines: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 6.17 Selected Late-Stage Adult Prophylactic Vaccines Pipeline, 2012

Table 6.18 Selected Prophylactic Anthrax Vaccines Pipeline, 2012

Table 6.19 Selected Prophylactic Dengue Fever Vaccines Pipeline, 2012

Table 6.20 Selected Prophylactic Hepatitis Vaccines Pipeline, 2012

Table 6.21 Selected Prophylactic Malaria Vaccines Pipeline, 2012

Table 6.22 Selected Prophylactic Ebola Virus Vaccines Pipeline, 2012

Table 6.23 Selected Prophylactic Cytomegalovirus Vaccines Pipeline, 2012

Table 6.24 Selected Prophylactic Streptococcal Vaccines Pipeline, 2012

Table 6.25 Selected Prophylactic Staphylococcal Vaccines Pipeline, 2012

Table 6.26 Selected Other Adult Prophylactic Vaccines in Development, 2012

Table 6.27 Selected Other Adult Prophylactic Vaccines in Phase I Development, 2012

Table 6.28 Selected Prophylactic HIV Vaccines Pipeline, 2012

Table 6.29 Selected Prophylactic HIV Vaccines Phase I Pipeline, 2012 

Table 6.30 Summary of Leading Products in the Adult Prophylactic Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 6.31 Summary of Leading Products in the Adult Prophylactic Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 7.1 Therapeutic Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016

Table 7.2 Therapeutic Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022

Table 7.3 Provenge: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 7.4 Provenge: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 7.5 Therapeutic Cancer Vaccines: Late-Stage Pipeline, 2012

Table 7.6 Therapeutic Cancer Vaccines: Selected Pipeline Products, 2012 

Table 7.7 Therapeutic Allergy Vaccines: Selected Pipeline Products, 2012 

Table 7.8 Therapeutic Addiction Vaccines: Selected Pipeline Products, 2012 

Table 7.9 Therapeutic Chronic Infectious Disease Vaccines: Selected Pipeline Products, 2012 

Table 7.10 Therapeutic Vaccines for Other Chronic Diseases: Selected Pipeline Products, 2012 

Table 7.11 Summary of Leading Products in the Therapeutic Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2011-2016

Table 7.12 Summary of Leading Products in the Therapeutic Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2017-2022

Table 10.1 Selected Vaccines in Late-Stage Development, 2012

List of Figures

Figure 3.1 World Vaccines Market: Revenues ($bn), 2011-2022

Figure 3.2 World Vaccines Market Segments: Revenues ($bn), Overall Market Shares (%), 2011

Figure 3.3 World Vaccines Market Segments: Revenues ($bn), 2011-2022

Figure 3.4 Leading Companies in the Vaccines Market: Revenues ($bn), Overall Market Shares (%), 2011

Figure 3.5 Leading Regions in the Vaccines Market: Revenues ($bn), Overall Market Shares (%), 2011

Figure 3.6 World Vaccines Market Regions: Revenues ($bn), 2011-2022

Figure 3.7 EU5 Vaccines Market Breakdown by Country: Revenues ($bn), 2011-2022

Figure 3.8 BRIC Vaccines Market Breakdown by Country: Revenues ($bn), 2011-2022

Figure 4.1 Paediatric Vaccines Market: Revenues ($bn), 2011-2022

Figure 4.2 Drivers and Restraints for Paediatric Vaccines, 2012

Figure 4.3 Leading Products in the Paediatric Vaccines Market: Revenues ($bn), Market Shares (%), 2011

Figure 4.4 Drivers and Restraints for Prevnar-13, 2012

Figure 4.5 Leading Products in the Paediatric Pneumococcal Vaccines Market: Revenues ($bn), Market Shares (%), 2011

Figure 4.6 Prevnar-13: Revenues ($bn), 2011-2022

Figure 4.7 Drivers and Restraints for Pentacel/Pediacel/Pentaxim/Others, 2012

Figure 4.8 Pentacel/Pediacel/Pentaxim/Others: Revenues ($bn), 2011-2022

Figure 4.9 ProQuad /MMR-II/Varivax Revenues ($bn), 2009-2011

Figure 4.10 Drivers and Restraints for ProQuad/MMR-II/Varivax, 2012

Figure 4.11 ProQuad/MMR-II/Varivax: Revenues ($bn), 2011-2022

Figure 4.12 Infanrix/Pediarix/Others Revenues ($bn) by Region, 2011

Figure 4.13 Drivers and Restraints for Infanrix/Pediarix/Others, 2012

Figure 4.14 Infanrix/Pediarix/Others: Revenues ($bn), 2011-2022

Figure 4.15 Division of the Rotavirus Vaccine Market, 2011

Figure 4.16 Drivers and Restraints for RotaTeq, 2012

Figure 4.17 RotaTeq: Revenues ($bn), 2011-2022

Figure 4.18 Other Paediatric Vaccines: Revenues, 2011-2022

Figure 4.19 Summary of Leading Products in the Paediatric Vaccines Market: Revenues ($bn), 2011-2022

Figure 5.1 Influenza Vaccines: Revenues ($bn), 2011-2022

Figure 5.2 Drivers and Restraints for Influenza Vaccines, 2012

Figure 5.3 Drivers and Restraints for Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others, 2012

Figure 5.4 Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others: Revenues ($bn), 2011-2022

Figure 5.5 Drivers and Restraints for Fluarix/Flulaval, 2012

Figure 5.6 Fluarix/Flulaval: Revenues ($bn), 2011-2022

Figure 5.7 Summary of Leading Products in the Influenza Vaccines Market: Revenues ($bn), 2011-2022

Figure 6.1 Adult Prophylactic Vaccines: Revenues ($bn), 2011-2022

Figure 6.2 Drivers and Restraints for Adult Prophylactic Vaccines, 2012

Figure 6.3 Leading Products in the Adult Prophylactic Vaccines Market: Revenues ($bn), Market Shares (%), 2011

Figure 6.4 Drivers and Restraints for Gardasil, 2012

Figure 6.5 Gardasil: Revenues ($bn), 2011-2022

Figure 6.6 Chronic Hepatitis B: Global Prevalence by Region, 2012

Figure 6.7 Drivers and Restraints for Engerix/Fendrix/Havrix/Twinrix/Ambirix, 2012

Figure 6.8 Engerix/Fendrix/Havrix/Twinrix/Ambirix: Revenues ($bn), 2011-2022

Figure 6.9 HPV Vaccine Market Shares (%), 2011

Figure 6.10 Cervarix Sales by Region (%), 2011

Figure 6.11 Drivers and Restraints for Cervarix, 2012

Figure 6.12 Cervarix: Revenues ($bn), 2011-2022

Figure 6.13 Drivers and Restraints for Menactra and Other Meningitis/Pneumonia Vaccines, 2012

Figure 6.14 Menactra and Other Meningitis/Pneumonia Vaccines: Revenues ($bn), 2011-2022

Figure 6.15 Adult Booster Market Shares (%), 2011

Figure 6.16 Drivers and Restraints for Adacel and Other Adult Boosters, 2012

Figure 6.17 Adacel and Other Adult Boosters: Revenues ($bn), 2011-2022

Figure 6.18 Other Adult Prophylactic Vaccines: Revenues ($bn), 2011-2022

Figure 6.19 Summary of Leading Products in the Adult Prophylactic Vaccines Market: Revenues ($bn), 2011-2022

Figure 7.1 Therapeutic Vaccines Market: Revenues ($bn), 2011-2022

Figure 7.2 Drivers and Restraints for Therapeutic Vaccines, 2012

Figure 7.3 Drivers and Restraints for Provenge, 2012

Figure 7.4 Provenge: Revenues ($bn), 2011-2022

Figure 7.5 Summary of Leading Products in the Therapeutic Vaccines Market: Revenues ($bn), 2011-2022

Figure 10.1 Vaccine World Market Revenues ($bn), 2011-2016

Figure 10.2 Vaccine World Market Revenues ($bn), 2017-2022

Figure 10.3 Vaccine World Market Segments: Revenues ($bn), 2011-2016

Figure 10.4 Vaccine World Market Segments: Revenues ($bn), 2017-2022

Figure 10.5 Leading 10 Vaccine Franchises of 2011: Revenues ($bn), 2011-2022 

Companies Listed

Aaron Diamond AIDS Research Center

Abbott Laboratories 

Acambis

ACE Biosciences

Activartis Biotech

Adamis Pharmaceuticals

Aduro BioTech

Advaxis

Aerus Global TB Vaccine Foundation

Affiris

Agenus

Akela Pharma

ALK Abello

Allergy Therapeutics

Allertein Therapeutics

AlphaVax

Antigen Express

Antigenics

Aphton

Argos Therapeutics

Astellas Pharma US

AstraZeneca

AuRx

AVAX Technologies

Avant Immunotherapeutics

Baxter Healthcare

Bayer HealthCare

Bayhill Therapeutics

Bellicum Pharmaceuticals

Bharat Biotech

Biken Japan

Biogen Idec

Bill & Melinda Gates Foundation

Biomira

Bionor Pharma

BioSante Pharmaceuticals

Biotech Synergy

Biovest International

BN ImmunoTherapeutics (Bavarian Nordic)

Cancer Advances 

CancerVax

Cell Control

Celldex Therapeutics

Cell Genesys

Celltech

CEL-SCI

Celtic Pharma

Centers for Disease Control and Prevention (CDC)

CG Therapeutics

Chemo-Sero-Therapeutic Research Institute

Chiron

Colby Pharmaceutical

Coley Pharmaceuticals

Corixa 

Cosmo Pharmaceuticals

Crucell

CSL Behring

Cytokine PharmaSciences

Cytos Biotechnology

DBV Technologies

Dendreon

Denka Seiken

Department of Defense (US) 

Dynavax Technologies 

DynPort Vaccine 

EMD Serono

Emergent BioSolutions

Endocyte

Epeius Biotechnologies

Etubics

European Medicines Agency (EMEA/EMA)

Evans Medica

Favrille

Food and Drug Administration (US FDA)

Galena Biopharma

GeneCure Biotechnologies

Genentech

Genetic Immunity

Genitope

GenPhar

GenVec

GeoVax Labs

Geron

GlaxoSmithKline (GSK)

GlobeImmune

Gradalis

Greer Laboratories

Hawaii Biotech

Heat Biologics

iBio

Ichor Medical Systems

immatics biotechnologies

Immunitor

ImmunoCellular Therapeutics

Immunocore

Immunofrontier

Immunotope

Immunovaccine

Infectious Diseases Research Institute

Inovio Pharmaceuticals

Institut Pasteur

Intercell 

Intercell USA

International Vaccine Institute

Intracel

Inviragen

Janssen Alzheimer Immunotherapy

JN-International Medical

Johns Hopkins University

KAEL-GemVax

Kitasato Institute

LigoCyte Pharmaceuticals 

Liquidia Technologies

Ludwig Institute for Cancer Research

MabVax Therapeutics

MaxCyte

Medeva

Medicago USA

MedImmune

Medirace

Memgen

Menarini

Merck & Co.

Merck KGaA

Meridian Biosciences

Momotaro-Gene

Nabi Biopharmaceuticals

NanoBio

Nanotherapeutics

National Institutes of Health (NIH, US)

Neurological Disorders

NewLink Genetics

Northwest Biotherapeutics

Novadigm Therapeutics

Novartis

NovaRx

Novavax

Novo Energies

NuVax Therapeutics

Okairos

Oncothyreon

OncoVax

Opal Therapeutics

Optimer Pharmaceuticals

Orban Biotech

Oxford BioMedica

PaxVax

Pfizer

PharmAthene

Pique Therapeutics

Polynoma 

Powderject

Prima Biomed

Profectus Biosciences

Progenics Pharmaceuticals

Protein Sciences

Quantum Immunologics

Quest PharmaTech

Roche

Sabin Vaccine Institute

Sanaria

Sanofi

Sanofi Pasteur

Selecta Biosciences

Sinovac

Soligenix

Stallergenes

Stemline Therapeutics

Takeda

Teva Pharmaceutical Industries

The GAVI Alliance

Theraclone Sciences

Thymon

Transgene

TVAX Biomedical

UNICEF

United Biomedical

University of Queensland

University Hospital of Tubingen

US Naval Medical Research Center

Vaccine Research Center (NIAID)

Vaccine Technologies

Vaccinogen

Vaxart

VaxGen

Vaxin

VaxInnate

VaxOnco

Vical

WHO (World Health Organization)

Xcellerex 

To order this report:

Drug_and_Medication Industry: World Vaccines Market 2012-2022

Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Back to top

RELATED LINKS
http://www.reportlinker.com


Source: www.prnewswire.com

No comments:

Post a Comment